Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?

Hepatology

Volumn 53, Issue 2, 2011, Pages 715-716

  Thevenot, Thierry ^a   Cervoni, Jean Paul ^a   Monnet, Elisabeth ^a   Sheppard, Frances ^b   Martino, Vincent Di ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HÔPITAL SAINT JACQUES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

ASCITES; BACTERIAL PERITONITIS; DRUG EFFECT; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY DYSFUNCTION; LETTER; LIVER CIRRHOSIS; PARACENTESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ASCITES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; PROPRANOLOL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79251523827     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23839     Document Type: Letter

References (10)

1. Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. HEPATOLOGY 2010; 52: 1017-1022.
2. Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol; doi:10.1016/j.jhep.2010.03. 021.
3. Pérez-Paramo M, Muñoz J, Albillos A, Freile I, Portero F, Santos M, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. HEPATOLOGY 2000; 31: 43-48.
4. Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006; 45: 744-757.
5. Such J, Frances R, Munoz C, Zapater P, Casellas JA, Cifuentes A, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. HEPATOLOGY 2002; 36: 135-141.
6. Zapater P, Francés R, González-Navajas JM, de la Hoz MA, Moreu R, Pascual S, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. HEPATOLOGY 2008; 48: 1924-1931.
7. Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006; 101: 506-512.
8. De Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-176.
9. Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29: 1189-1193.
10. Triantos C, Vlachogiannakos J, Manolakopoulos S, Burroughs A, Avgerinos A. Is banding ligation for primary prevention of variceal bleeding as effective as beta-blockers, and is it safe? HEPATOLOGY 2006; 43: 196-197.